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1. Introduction 
1.1. Overview of drug disposition and response in critically ill patients  
Therapeutic hypothermia has been growing in use over the past several years. Proven 
efficacy of therapeutic hypothermia in pediatric hypoxic-ischemic encephalopathy (HIE) 
patients and adult out-of-hospital cardiac arrest (CA) patients has led to expanding clinical 
implementation in both large and small hospitals. Furthermore, its use to control 
intracranial pressure (ICP) in brain injured patients, as well as ongoing experimental studies 
for a variety of other conditions, have led to increased use of therapeutic hypothermia in the 
intensive care unit (ICU). With increased implementation comes a growing need to 
understand the ramifications of therapeutic hypothermia on other important factors of ICU 
care. One such factor is drug disposition and efficacy changes in the hypothermic patient. 
Specifically, clinical practitioners have postulated the question, “Should drug doses be 
altered during or after cooling in patients receiving therapeutic hypothermia?” The purpose 
of this chapter is to explore this question and present the current understanding of the 
effects of mild therapeutic hypothermia on the processes of absorption, distribution, 
metabolism and excretion, as well as provide specific evidence of drugs with altered and 
unaltered pharmacokinetics.  
The question of altered drug disposition and response in patients receiving therapeutic 
hypothermia is particularly important due to the wide array of drugs used in critically ill 
patients. Critically ill patients are known to have a high rate of adverse drug events. This 
high rate of adverse drug events is due, in part, to the plethora of medications used for 
analgesia/sedation, paralysis, control of seizure activity, blood pressure, treatment of 
arrhythmias, control of blood clotting, antibiotics, and delirium prevention. Table 1 provides 
a list and details the pharmacokinetic characteristics of the medications commonly 
administered to critically ill patients organized by class of compound. From this table, it is 
 Therapeutic Hypothermia in Brain Injury 132 
clear that many of these drugs have large volumes of distribution, are extensively bound to 
plasma proteins, and require hepatic metabolism as a primary mechanism of elimination. 
2. Physiologic effects of therapeutic hypothermia  
Before discussing the specific effects of therapeutic hypothermia on drug disposition and 
response, it is important to first recognize the general physiologic changes that occur in 
therapeutic hypothermia patients during induction, maintenance, and rewarming. In a 
broad sense, therapeutic hypothermia is defined as a core temperature less than 35.0˚C. 
Moreover, there are different degrees of hypothermia which incur a range of 
neuroprotection and adverse physiologic effects. Hypothermia can be divided based on the 
degree of cooling and include mild hypothermia, moderate hypothermia, and severe 
hypothermia. It is generally accepted that mild hypothermia occurs when a subject is cooled 
to a temperature of 32-34˚C whereas moderate hypothermia is at a temperature range of 30 – 
32˚C. Severe, or “deep” hypothermia, is defined as cooling to a temperature below 30˚C. 
Furthermore, therapeutic hypothermia undergoes different lengths of cooling depending on 
the subject population. Adult cardiac arrest patients typically undergo therapeutic 
hypothermia for 24-48 hours, whereas neonates with HIE are cooled for 72 hours. The 
duration of cooling is largely based on the design of randomized control trials which 
demonstrated outcome benefits. 
Although these temperatures tend to be generally accepted, it is important to note that these 
categories can be arbitrary across studies and require verification of temperature and 
duration in the currently published literature. In order to normalize the temperatures 
discussed in this chapter, we have focused predominately on the effects seen within mild 
hypothermia (32-34˚C), since this is the clinically relevant temperature range that has been 
proven to afford neuroprotection without adverse physiologic consequences to patients in 
the ICU.  
a. Cardiovascular effects 
Hemodynamic Effects: Hypothermia has been linked to changes in myocardial function. Mild 
hypothermia induces a decrease in heart rate, but produces an overall increase in the 
contractility of the heart in sedated patients. Systolic function will improve, but diastolic 
function may decrease. Some patients may experience an increase in blood pressure while 
others may see no change in blood pressure. Overall, cardiac output will decrease along 
with the heart rate. However, the subsequent hypothermia-induced decrease in metabolic 
demand tends to equal or exceed the decrease in cardiac output, thus keeping the balance 
between supply and demand constant. Generally, cold diuresis occurs early during cooling 
and is of a relatively short duration.  
In some cases, the heart rate may be artificially increased by drugs or external pacing. 
However, the effect of hypothermia on myocardial contractility has convoluted results 
under artificial stimulation. Two pre-clinical studies showed that under normothermic 
conditions an increase in heart rate led to an increase in cardiac output and myocardial 
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contractility. In contrast, when heart rate was increased under mild hypothermic conditions 
there was a decrease in myocardial contractility. The same results were reported in a clinical 
study in patients undergoing cardiac surgery. When heart rate was not increased artificially, 
mild hypothermia improved myocardial contractility. Thus, in most patients heart rate 
should be allowed to decrease with temperature without any serious adverse complications. 
Electrocardiographic Effects: Mild hypothermia has also been associated with abnormal heart 
rhythms. During cooling, hypothermia causes an increase in plasma norepinephrine levels 
and activation of the sympathetic nervous system. This leads to constriction of peripheral 
vessels and a shift of the blood from small, peripheral veins to centrally located veins in the 
core compartment of the body. Ultimately, this results in an increase in venous return which 
leads to mild sinus tachycardia. As temperature continues to drop even further below 35˚C, 
the heart rate begins to slow to a below normal rate eventually leading to what is known as 
sinus bradycardia. The heart rate will continue to decrease progressively as temperature 
drops to 33˚C and below. The mechanism behind this is a decrease in the rate of 
spontaneous depolarization of cardiac cells in combination with prolonged duration of 
action potentials. These electrocardiogram changes usually do not require treatment and in 
most cases a patient’s heart rate should be allowed to decrease with cooling. 
Furthermore, some studies have linked hypothermia to an increased risk for arrhythmias. 
However, hypothermia-induced arrhythmias generally only apply to moderate to deep 
hypothermia, particularly when temperatures reach less than 30°C. During deep 
hypothermia, a patient is at higher risk to develop atrial fibrillation or ventricular fibrillation 
if temperatures reach as low as 28°C. Since temperatures are maintained at greater than 
30°C in the ICU, few cases of hypothermia-induced arrhythmias have been observed in 
clinical trials evaluating the safety of mild therapeutic hypothermia.  
b. Renal effects 
Therapeutic hypothermia also has physiologic effects on renal function. During cooling, an 
increase in urinary output, known as cold diuresis, may occur. Cold diuresis results from a 
combination of an increase in venous return, a decrease in antidiuretic hormone, tubular 
dysfunction, and decreased levels of antidiuretic hormone and renal antidiuretic hormone 
receptor levels. 
Renal elimination can be divided into passive filtration, active tubular secretion and active 
tubular reabsorption. Passive glomerular filtration does not seem to be affected by 
therapeutic hypothermia. One clinical study investigated the effects of mild hypothermia on 
renal filtration by measuring serum creatinine levels and creatinine clearance in subjects 
with and without hypothermic treatment. The study found no change in creatinine 
clearance between the two groups and concluded that cooling does not impair renal 
filtration.  
Although passive processes of renal filtration do not seem to be significantly altered, some 
published evidence does suggest that the active processes of tubular secretion and 
reabsorption may be altered by mild hypothermia. To date, the effect of therapeutic 
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hypothermia on the active process of tubular secretion has only been studied preclinically in 
rats. This study used fluorescein isothiocyanate (FITC)-dextran to measure glomerular 
filtration and phenolsulfonphthalein (PSP) to measure renal tubular secretion in mildly 
hypothermic versus normothermic rats. The results showed no change in FITC-dextran 
clearance, but a significant change in the renal clearance of PSP. These results provide 
further evidence that the passive process of renal filtration is unaffected by mild 
hypothermia, whereas, active renal tubular secretion is decreased during cooling. There are, 
however, a limited number of studies published to date and whether or not these initial 
evaluations remain true clinically will depend on more extensive assessments of the effects 
of mild hypothermia on renal drug elimination processes. 
c. Electrolyte effects 
Therapeutic hypothermia also alters electrolyte levels such as magnesium, potassium, and 
phosphate. During cooling, electrolytes shift from the bloodstream to the intracellular 
compartment. The low level of electrolytes remaining in the bloodstream increases a 
patients risk for hypokalemia. During rewarming, the opposite effect is seen and potassium, 
as well as other electrolytes, is released back into the bloodstream from the intracellular 
compartment. If the patient is rewarmed too quickly, potassium levels will increase abruptly 
in the bloodstream and the patient may become hyperkalemic. To avoid hyperkalemia, a 
slow and consistent rewarming period is necessary to allow the kidneys to excrete the excess 
potassium. Furthermore, frequent lab electrolyte assessments are needed to account for 
shifts in systemic electrolyte concentrations.  
d. Body metabolism & drug clearance effects 
Hypothermia has been shown to decrease the metabolic rate by approximately 8% per 1˚C 
drop in body temperature. A similar decrease in oxygen consumption and carbon dioxide 
production is observed. This decrease in metabolic rate arises from a global decrease in the 
rate of drug metabolism by the liver because the majority of the metabolic reactions in the 
liver are enzyme-mediated. The rate of these enzyme-mediated reactions is highly 
temperature sensitive; thus the rate of these reactions is significantly slowed during 
hypothermia. Hypothermia-induced reductions in clearance have been shown for a number 
of commonly used ICU sedatives such as propofol; opiates such as fentanyl and morphine; 
midazolam; neuromuscular blocking agents such as vecuronium and rocuronium; and other 
drugs such as phenytoin (Refer to Table 1). The specific alterations in drug metabolism and 
clearance will be further addressed in the upcoming sections of this chapter.  
e. Gastrointestinal effects 
Gastrointestinal (GI) motility decreases with mild hypothermia. In some cases, decreased 
motility leads to mild ileus which typically occurs at temperatures less than 32°C. Other 
physiological factors play a large role in the extent to which drugs and nutrients are 
absorbed across the gut wall. As with drug excretion in the kidney, drug absorption across 
the intestinal membranes depends primarily on passive diffusion with significant 
 
Therapeutic Hypothermia: Implications on Drug Therapy 135 
contribution by active transport mechanisms for some drugs. Also similar to the kidney, 
cooling was shown to affect active drug transport via the ABCB1 transporter, more 
commonly known as P-glycoprotein, in vitro. However, no affect of cooling has been 
reported on passive diffusion, thereby, suggesting that passive processes are unaltered and 
active drug transport may be impaired during cooling. Further physiological factors that 
affect absorption include the pH of various biological compartments and the blood flow at 
the site of absorption. The physiochemical properties of the drug, such as its pKa and lipid 
solubility, in combination with the compartmental pH, will influence the extent of which the 
drug will distribute into a given compartment. It is expected that some drugs will have 
increased absorption while others may have decreased absorption during cooling 
depending on pH, lipophilicity, and primary site of GI absorption; however, no studies to 
date have thoroughly evaluated if these anticipated changes occur in vivo under mild 
hypothermic conditions. The effects of hypothermia on drug disposition and response will 
be further addressed in the next section. 
 
ANALGESICS 
/SEDATIVE 
Primary Route of 
Elimination 
Pathway(s) of 
Elimination 
Volume of 
Distribution
Protein 
Binding 
Half-
life 
Fentanyl Hepatic: 75%  CYP3A4 4 - 6 L/kg 80-85% 3-12 hrs 
Propofol Hepatic: 90% CYP2B6/UGT 60 L/kg 95-99% 30-60 
mins 
Dexmedetomidine Hepatic: 95%  CYP2A6 118 - 152 L/kg94% 2-2.67 
hrs 
Remifentanil Hepatic: 90% Metabolized by  
esterases in blood  
and tissue 
0.35 L/kg 92% 3-10 
mins 
Midazolam Hepatic: 63 - 80%  CYP3A4  1 - 3.1 L/kg 
 
95% 1.8-6.4 
hrs 
Lorazepam Hepatic: 88%  Conjugation 1.3 L/kg 91%  9-19 hrs 
Ketamine Hepatic CYP3A4 (major), 
CYP2B6 & CYP2C9 
(minor) 
2 - 3 L/kg 47% 2-3 hrs 
Morphine Hepatic: 90% UGT2B7, CYP2C, 
CYP3A4 
1 - 4.7 L/kg 30-40% 2-3 hrs 
PARALYTICS      
Vecuronium Bile: 30 – 50% Renal:  
3 – 35% Hepatic: 15% 
CYP3A4 0.2 - 0.4 L/kg 60 - 80% 51-80 
mins 
Rocuronium Bile:  Extensive 
Renal:  33% 
Hepatic:   Minimal 
CYP2D6/Renal 0.25 L/kg  30% 84-131 
mins 
Pancuronium Renal:  50 – 70% Hepatic:  
15%  Bile:  5 – 10% 
Renal elimination & 
Bile 
0.19 L/kg 77-91% 1.5-2.7 
hrs 
ANTI-ARRYTHMICS      
Lidocaine Hepatic: 90% CYP1A2 (major), 
CYP3A4 (minor) 
1.5 L/kg 60-80% 1.5–2.0 
hrs 
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ANALGESICS 
/SEDATIVE 
Primary Route of 
Elimination 
Pathway(s) of 
Elimination 
Volume of 
Distribution
Protein 
Binding 
Half-
life 
Amiodarone Hepatic:  Extensive CYP3A4, CYP2C8 60 L/kg 33-65% 15-142 
days 
Digoxin Renal: 55 – 80%  
Bile: 6 – 8% 
glomerular filtration, 
PGP Transporter 
4 - 7 L/kg 25% 36-48 
hrs 
Diltiazem Hepatic: Extensive CYP450s 3 - 13 L/kg 77-93% 3-6.6 
hrs 
ANTI-
HYPERTENSIVE 
     
Verapamil Hepatic:  65 – 80% CYP3A4, CYP2C9/19; 
PGP Transporter 
3.8 L/kg 90% 3-7 hrs 
Enalapril Hepatic: 60 - 70% Hydrolyzed in liver, 
OATP/MRP2 
Transporter 
0.2 – 0.4 L/kg 50-60% 11 hrs 
Metoprolol Hepatic: 95% CYP2D6 5.6 L/kg 15% 3-7 hrs 
Valsartan Feces: 83%  
Hepatic: 7-13% 
Primarily excreted as 
unchanged drug; 
OATP/MRP2 
Transporter 
17 L/kg 95% 6 hrs 
Pressors and Iontropes      
Epinephrine Hepatic & other tissues Metabolized by MAO 
& COMT 
N/D N/D 2 mins 
Norepinephrine Hepatic & other tissues Metabolized by MAO 
& COMT 
N/D N/D 2 mins 
Phenylephrine GI Tract:  Extensive Metabolized by MAO 
& sulfotransferase 
40 L/kg N/D 2-3 hrs 
Milrinone Renal: 80 - 85% Primarily excreted as 
unchanged drug; 
Active tubular 
secretion  
0.3 - 0.47 L/kg70% 1-3 hrs 
Dopamine Hepatic: 80% Metabolized by MAO 
& COMT 
1.8 - 2.5 L/kg N/D 9 mins 
Vasopressin Hepatic and Renal:  
Extensive 
Metabolized by 
vasopressinases  
N/D N/D 10-20 
mins 
ANTI-CONVULSANT      
Phenytoin Hepatic:  Extensive   CYP2C9, CYP2C19; 
UGT Transporter 
0.5 - 1.0 L/kg 90% 7-42 hrs 
Phenobarbital Hepatic CYP2C9; UGT 
Transporter 
0.5 – 1.9 L/kg 20-45% 2–7 
days 
Carbamazepine Hepatic: 72% 
Feces: 28% 
CYP3A4, CYP2C9; 
PGP/UGT 
Transporters 
0.8 - 2 L/kg 76% 25-65 
hrs 
Keppra Renal: 66% Hepatic:  
minimal 
Primarily excreted as 
unchanged drug; 
some enzymatic 
hydrolysis 
0.7 L/kg < 10% 6-8 hrs 
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ANALGESICS 
/SEDATIVE 
Primary Route of 
Elimination 
Pathway(s) of 
Elimination 
Volume of 
Distribution
Protein 
Binding 
Half-
life 
ANTI-PLATELET/
CLOTTING 
     
Warfarin  Hepatic: 92% Primarily CYP2C9 
but also CYP2C19, 
CYP1A2, CYP2C8 & 
CYP3A4 
0.14 L/kg 99.5% 20-60 
hrs 
Heparin Hepatic Metabolized by 
heparinise; cleared 
via 
reticuloendothelial 
system 
0.07 L/kg N/D 1-2 hrs 
Dalteparin Hepatic:  extensive Primarily by 
desulfation and 
depolymerization 
0.04 – 0.06 
L/kg 
Low 3-5 hrs 
Aspirin Hepatic Hydrolyzed by 
esterases in the liver 
to active metabolite 
0.15 L/kg 50-80% 4.7-9 
hrs 
Clopidogrel Hepatic:  Extensive CYP2C19, CYP3A4, 
CYP1A2 and 
esterases 
 98% 6 hrs 
Rivaroxaban Hepatic: Extensive  
Renal:  36% 
CYP3A4/5 & CYP2J2 50 L/kg 92-95% 5-9 hrs 
Dabigatran Hepatic: 80%  esterases and 
glucuronidation  
50-70 L/kg 35% 12-17 
hrs 
MISCELLANEOUS      
Quetiapine Hepatic: 70 - 73% CYP3A4 6 - 14 L/kg 83% 6 hrs 
Haloperidol Hepatic: 50-60%  
Feces: 15% 
Glucuronidation; 
CYP3A4 
9.5 - 21.7 L/kg90% 18 hrs 
Gentamicin  
Renal: 80 - 100% 
glomerular filtration 0.2 - 0.3 L/kg <30% 1.5-3 
hrs 
Piperacillin / 
Tazobactam 
Renal:  70 - 90% glomerular filtration 
and tubular secretion
0.18 - 0.3 L/kg16% 36-80 
mins 
Vancomycin Renal:  40 - 100% glomerular filtration 0.2 - 1.25 L/kg30-55% 4 – 6 
hrs 
Pravastatin Hepatic:  Extensive Extensive first pass 
extraction by the liver
0.46 L/kg 43-55% 2.6-3.2 
hrs 
Pantoprazole Hepatic: 71% 
Feces: 18% 
CYP2C19/CYP3A4 11 - 24 L/kg 98% 1 hr 
Famotidine Renal: 25 - 70% glomerular filtration 
and tubular secretion
1 L/kg 15-20% 8-12 hrs 
Corticosteroids Hepatic CYP3A4 Varies Varies Varies 
Abbreviations:  N/D: not determined; mins: minutes; hrs: hours; PGP: P-glycoprotein; UGT: UDP-galactose 
transporter; MAO: monoamine oxydase; COMT: catechol-O-methyltransferase; OATP: organic anion transporter; 
MRP2: Multidrug resistance protein 2. 
Table 1. Pharmacokinetic characteristics of commonly used medications in critically ill patients 
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3. The effects of therapeutic hypothermia on drug pharmacokinetics  
In general, hypothermia can affect drug disposition in various ways. We have previously 
discussed the physiological changes induced by hypothermia. These effects generally 
include decreases in active transport processes of drug absorption and excretion, no 
alteration in passive processes of drug disposition, and a general reduction in the overall 
rate of drug metabolism. Although these are general alterations, it is important to note that 
each of these alterations have been shown to be drug specific and requires particular 
evaluations of drug disposition in the cooled patient. In addition, hypothermia is also 
known to alter the different phases of drug pharmacokinetics. These phases can be broken 
up into absorption, distribution, metabolism and transport, and excretion. This section will 
highlight the effect of therapeutic hypothermia on each of these four phases, and the current 
research in the area. A summary of the current clinical studies on drug disposition is given 
in Table 2. In addition, Figure 1 summarizes the known physiologic and drug disposition 
effects of hypothermia and provides a statement of the level of evidence that currently exists 
in the published literature.  
a. Drug absorption effects 
Most drugs in the ICU are administered intravenously. However, some drugs are given 
non-intravenously, typically via oral administration. Drugs that are administered orally are 
subject to many factors that influence the rate and amount of drug that can be absorbed 
before it reaches the bloodstream. Some of these factors, such as disintegration and 
dissolution, are drug dependent and will vary among drugs based on their dosage form 
(tablet, capsule, etc) as well as the components that make up the drug (active ingredient, 
excipients, etc). Physiochemical properties of the drug, such as the pKa, lipophilicity, and 
solubility, will also influence the total amount of drug absorbed.  
As previously addressed in the physiology section, gastrointestinal motility is known to 
decrease with mild hypothermia. Furthermore, a decrease in temperature can decrease 
blood flow at the site of absorption, and increase or decrease the gastric and duodenal pH, 
all factors that will ultimately affect a drug’s absorption.  
Pre-clinical studies investigated the effects of moderate hypothermia on these physiological 
factors. Hypothermia is associated with a decrease in passive transport via ABCB1. Results 
demonstrated a 30-44% decrease in the absorption rate constant, ka, of pentobarbital, 
levodopa and uracil. However, these pre-clinical studies induced moderate or severe 
hypothermia. Therefore, the decrease in drug absorption may be more pronounced than 
what would be observed clinically under mild hypothermia.  
Overall, the effect of hypothermia on drug absorption may lead to a decreased rate and 
prolonged time to reach maximal concentration for some drugs. Furthermore, the time of 
onset may be delayed and the magnitude of the pharmacological response, due to these 
reduced concentrations, may be diminished. However, current studies do not accurately 
reflect the range of temperature cooling in vivo and further clinical studies need to be done 
to determine if the magnitude of alterations in drug absorption is clinical relevant. 
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Study Group Subject Population/
Temperature Cooled
Drug Route of 
Elimination
Concentration & PK 
Parameters 
Preclinical 
Studies 
 
Tortorici et al. 
[26] 
CA rats/30˚C Chlorzoxazone CYP2E1 ↓CLs, t1/2, ke. ↑ Vd 
Koren et al. [45] Piglets/31.6˚C Fentanyl CYP3A4 ↑Plasma 
concentrations, ↓ CLs,  
↓Vd, ↑half-life, 
Bansinath M. et 
al. [38] 
Dog/30˚C Morphine UGT, CYP2C, 
CYP3A4 
↑Plasma 
concentrations, ↓ CL 
70%,t1/2β ↑ 2-fold, Vd↓ 
Satas S. et al. [40] Hypoxia newborn 
pig/35°C
Gentamicin Renal Filtration No change in CL 
Nishida K. et al. 
[19] 
Rats/32°C PSP Renal Tubular 
Secretion 
Total CL↓ 42%, plasma 
AUC↑ 2-fold, renal 
secretion ↓ 
Jin J et al. [39] In vitro kidney 
epithelial cell/32˚C 
Digoxin Renal Filtration Direction from B to A ↓ 
50% 
  
Clinical Studies  
Fukuoka N. et al. 
[32] 
TBI Patients/32-34˚C Midazolam CYP3A4 Plasma concentration↑, 
Vd↑ 83%, CL↓, Ke↓ 
Beaufort A. M. 
et al. [46] 
Neurosurgical 
Patients/30.4˚C
Rocuronium CYP2D6/Renal CL↓to 51% 
Roka A. et al. 
[37] 
HIE Infants/33-34˚C Morphine UGT, CYP2C, 
CYP3A4
CL↓
Hostler D. et al. 
[33] 
Healthy 
volunteers/35.5-36.5°C
Midazolam CYP3A4 CL↓11% per degree 
Iida Y. et al. [25] Brain Damage 
Patients/34°C 
Phenytoin CYP2C9 & 
CYP2C19 
AUC↑180%, CL↓ 67% 
and Ke↓ 50% 
Liu X. et al. [20] HIE Infants/33.5°C Gentamicin Renal Filtration No change in CL 
Caldwell J. E. et 
al. [35] 
Volunteers/<35, 35-
35.9,36-36.9°C
Vecuronium CYP450s CL↓11.3% per degree 
  
Abbreviations: CL: Systemic clearance; AUC: Area under curve; Ke: Elimination rate; Vd: Volume of distribution; T1/2: 
Half- life. 
Table 2. Summary of the findings of clinical studies evaluating the effects of therapeutic hypothermia 
on drug disposition. 
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Figure 1. This figure depicts the known effects of therapeutic hypothermia on drug abosrption, 
distribution, metabolism, excretion and response. Also depicted is the quality of the current data with 
respect to each of these processes. 
b. Drug distribution effects 
When a drug is absorbed into the bloodstream, it distributes throughout the body into 
various tissues and organs. Generally, the space that the drug distributes into the body, or 
the volume of distribution (Vd), is important for drug dosing since it affects important 
pharmacokinetic parameters such as the loading dose and the half-life (t1/2) of the drug. The 
factors that influence drug distribution include protein binding, blood pH and lipophilicity. 
As previously stated, many of the drugs used in the ICU have relatively large volumes of 
distribution (Table 1), which implies that the drug compounds preferentially distribute into 
the tissues over the blood. With drugs that have large volumes of distribution it is common 
for this distribution to first occur into the easily perfused tissues, followed by a more 
delayed distribution into more difficult to perfuse tissues. 
Much of the effect of hypothermia on plasma protein binding is still largely unknown. Two 
in vivo studies (chlorzoxazone in rats and phenytoin in humans) showed unchanged plasma 
protein binding during hypothermia, whereas in vitro studies of sulfanilamide and lidocaine 
did show changes in the plasma protein binding. Sulfanilamide showed a 65% increase in 
plasma protein binding when cooled to 17˚C while lidocaine showed a 24% decrease in 
plasma protein binding when cooled to 24˚C. A possible explanation for the discrepancy 
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between in vitro and in vivo results could be the difference in cooling temperature. The in 
vitro studies cool to a much lower temperature than is possible in vivo (17˚C and 24˚C versus 
31˚C) and therefore may demonstrate a greater change in protein binding. To date, studies 
have not reported altered protein binding over the mild therapeutic hypothermia 
temperature range. 
Another factor that is influenced by hypothermia is the pH of the blood. As temperature 
decreases, the partial pressure of carbon dioxide decreases and the pH increases. For every 
10 degree change in temperature, the blood pH increases from 7.40 to 7.55. Depending on 
the pKa of the drug, more or less of the drug will be ionized after the shift in pH. 
Consequently, more or less of the drug will be able to pass through permeable membranes. 
Theroretically, drugs like Lidocaine (pKa 7.9) that have a pKa between 7 and 8 may be most 
susceptible by these slight changes in blood pH. In vivo cooling is usually no more than a 6 - 
7˚C change. Thus, blood pH would be expected to change in small increments and the 
clinical effects of these changes remain to be elucidated.  
Finally, hypothermia may alter the lipid solubility and tissue binding of drugs. Preliminary 
studies demonstrate that hypothermia induced a decrease in transfer processes in water/n-
octanol systems of atenolol and pindolol. Furthermore, phenytoin was shown to have 
increased tissue binding in rats at higher temperatures potentially due to temperature- 
mediated changes in protein conformation, leading to an altered tissue binding capacity.  
Although hypothermia has been shown to have mixed effects on protein binding, blood pH, 
and lipophilicity at moderate to severe hypothermia, more studies are needed to determine 
the clinical magnitude and effects during mild hypothermia in patients. A change in any of 
these factors during mild hypothermia has the potential to alter the Vd of the drug. The 
limited number of published studies to date suggest no significant alteration in drug 
disposition during mild cooling, however, only a small number of drugs have been 
evaluated with respect to changes in distribution.  
c. Hepatic drug metabolism  
Many drugs that are administered to critically ill patients undergo extensive hepatic 
metabolism. These drugs are predominately metabolized by cytochrome P (CYP) enzymes. 
Various isoforms of the CYP450 enzyme family are involved in metabolism to varying 
degrees. These isoforms include CYP3A, CYP2C9 and CYP2C19, CYP2D6, and CYP2E1. Of 
these isoforms, CYP3A is one of the most important in hepatic drug metabolism in part due 
to its broad substrate specificity which allows for it to metabolize a wide range of 
compounds. Drugs commonly used in the ICU that are metabolized by CYP3A include 
midazolam, fentanyl, lidocaine, and vecuronium. 
Midazolam is a well-known CYP3A4 substrate that has been most extensively studied in 
therapeutic hypothermia. One clinical study looked at the effect of cooling on midazolam 
pharmacokinetics in patients with TBI. The normothermic group achieved a steady state 
concentration of midazolam which was maintained during the 216 hours. Conversely, the 
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hypothermic group never reached a steady state concentration and midazolam 
concentrations were about five-fold higher than the normothermic group. Further studies by 
Hostler et al. also saw a reduction in the clearance of midazolam during hypothermia. In this 
study normal, healthy volunteers were infused with cold saline and plasma samples were 
obtained to determine midazolam levels and clearance. A significant difference was 
observed in the overall metabolism of midazolam under mild hypothermic conditions. 
Furthermore, this study determined that midazolam clearance is reduced by 11% per degree 
Celsius change in temperature. Similarly, another preclinical study reported about a 17% 
decrease in midazolam clearance at steady state in hypothermic rats versus normothermic 
rats after cardiac arrest.  
Vecuronium, which is given as a muscle relaxant in the ICU, is another CYP3A4 substrate. 
The effect of hypothermia on vecuronium was studied in healthy human volunteers. 
Similarly to midazolam, the clearance of vecuronium was also decreased during cooling. 
Similarly, these studies demonstrated that an 11% reduction in vecuronium clearance is 
observed per degree Celsius change in body temperature. Furthermore, a preclinical study 
by Zhou et al demonstrated that hypothermia alters CYP3A activity, however the significant 
changes in CYP450 activity were isoform specific with significant alterations in CYP3A and 
CYP2E1 with no significant alteration in CYP2D or CYP2C probe metabolism. Collectively, 
these studies indicate that drugs which rely on CYP3A metabolism have decreased 
clearance during mild hypothermia, however, the reduced P450 activity appears to be 
isoform and potentially drug specific.  
In addition to CYP450 enzymes, Phase II enzymes also play an important role in the 
metabolism of many drugs used in critical care. Phase II enzymes include UDP-
glucuronosyltransferases (UGT), glutathione S-transferases, methyltransferases, 
sulfotransferases, and N-acetyltransferases. Of these enzymes, UGT is one of the only 
studied phase II enzymes and metabolizes a large number of drugs given in the ICU, such as 
morphine, propofol, phenobarbital, propranolol, aspirin, and acetaminophen. Of these, the 
effects of hypothermia on morphine have been most extensively studied. 
Morphine, a commonly administered analgesic in the ICU, is predominately metabolized by 
UGT2B7 with almost no metabolism by Phase I enzymes. One study measured morphine 
concentrations in neonates with hypoxic-ischemic encephalopathy (HIE). This randomized 
study compared peak serum morphine concentrations in neonates with HIE who were 
randomly assigned to either a hypothermic or normothermic group. After 72 hours, six of 
the seven neonates in the hypothermic group had morphine concentrations greater than 300 
ng/mL compared to one of six neonates in the normothermic group. Further, the clearance of 
morphine in the hypothermic group was significantly decreased. As previously mentioned, 
neonates undergo a longer, 72 hour duration of cooling. A pre-clinical animal study also 
showed a significant decrease in morphine clearance in the hypothermic model as compared 
to the normothermic model. These studies demonstrate a reduced clearance of midazolam 
during cooling. One possible explanation could be a decrease in UGT activity. Additional 
studies are needed on other UGT substrates to validate these results. 
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Digoxin is a calcium channel blocker used to treat arrhythmias in the ICU. A pre-clinical 
study of ABCB1 transport of digoxin showed that during mild hypothermia the rate of 
active transport was decreased. No difference in passive diffusion or tight junction activity 
was seen. The same group also studied the ABCB1-mediated transport of quinidine, another 
antiarrhythmic drug. In this study, no net effect was seen on quinidine transport during 
cooling. The authors propose that quinidine is also a substrate for the OATP transporter 
which may have influenced the results of temperature effects. Although these studies 
indicate that hypothermia may alter the active transport of drugs by ABCB1, further studies 
need to be completed to determine the in vivo relevance of these changes and explore the 
effects on other drug transporters.  
To date, most of the clinical and pre-clinical studies demonstrate a decrease in hepatic 
metabolism particularly with the CYP enzyme system during therapeutic hypothermia. 
Although there is a general reduction in drug metabolism, the magnitude of these 
alterations appears to be pathway specific and therefore, not all hepatically eliminated drugs 
will have reduced metabolism. In addition, many of these current clinical studies are small 
and underpowered. Additional studies still need to be performed to determine the extent of 
hepatic metabolism on drug concentrations and how clinicians can best dose patients 
receiving therapeutic hypothermia.  
d. Renal drug excretion  
Renal drug elimination is a common route of elimination for hydrophilic drugs. Renal 
elimination can be divided into filtration, tubular secretion and reabsorption. Filtration is a 
passive process, whereas tubular secretion is an active process of renal elimination. To date, 
few clinical studies exist that investigate the effect of hypothermia on renal drug 
elimination. A small number of preclinical studies have explored how cooling affects renal 
filtration and secretion.  
Gentamicin is a commonly administered drug in the ICU to treat infections, and 
predominately eliminated via passive filtration with little to no tubular secretion. Liu et al. 
showed that gentamicin concentrations remained unchanged in hypothermic neonates with 
HIE compared to normothermic neonates. This demonstrated that the clearance of 
gentamicin was not changed during mild hypothermia. Another study investigated the 
pharmacokinetics of gentamicin in piglets during mild hypothermia. They observed no 
change in gentamicin pharmacokinetics in hypoxic piglets versus normothermic piglets. 
These combined gentamicin studies coupled with the aforementioned evidence indicating 
no alterations in creatinine clearance suggest that mild hypothermia does not affect the 
passive process of renal filtration.  
In conclusion, these studies suggest that the passive processes of renal filtration are 
unaffected by mild hypothermia, whereas the active processes of renal tubular secretion 
may be decreased. However, these conclusions are based off of a single preclinical study in 
rats that investigated the active process of tubular secretion (previously discussed in renal 
physiology section). To accurately assess the effect of hypothermia on renal excretion, 
further studies in humans are needed. 
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4. The effects of therapeutic hypothermia on drug response 
In addition to the effects of therapeutic hypothermia on drug disposition and 
pharmacokinetics, hypothermia has also been associated with changes in drug response. 
The remainder of this section addresses drugs based on their therapeutic class and the 
current research showing changes in drug response. A summary of the clinical effects of 
hypothermia on drug response is given in Table 3. 
 
Study Group Subject population/ 
Temperature Cooled 
Drug Drug Response & PD 
Estimates 
Heier T. et al. [43] Patients undergoing 
surgery/34.5°C 
Vecuronium ↑Duration of Action PK 
mediated, ↑Recovery Time 
Leslie K. et al. [44] Healthy volunteers/34°C Atracurium ↑Response, ↑Duration of 
Action PK mediated 
Beaufort A.M. et al. [46] Neurosurgical 
patients/30.4°C 
Rocuronium ↑Duration of Action PK 
mediated 
Liu M. et al. [42] Children/ 34, 31°C Isoflurane ↓Dose Requirement 
Puig M.M. et al. [41] Guinea pig ileum/30°C Morphine ↓Affinity to receptor 
Bansinath M. et al. [38] Dog/30°C Morphine ↑Hypotension incidence  
Table 3. Summary of the findings of clinical studies evaluating the effects of therapeutic hypothermia 
on drug response.   
Analgesics/Sedatives. Medications given for analgesia and sedation are largely hepatically 
metabolized and are one of the most commonly used class of drugs in the ICU. We previously 
mentioned in the drug metabolism section that morphine is one of the most extensively 
studied analgesics and undergoes predominately Phase II enzyme metabolism by UGT2B7. 
The effect of hypothermia on morphine response was evaluated in a dog model. In the 
hypothermic group, a significant decrease in mean arterial pressure was observed, whereas no 
change in mean arterial pressure was seen in the normothermic group. Another in situ study 
measured the potency of morphine in guinea pig ileum. This study saw a decrease in the 
affinity of morphine for its target µ-receptor when the temperature was decreased from 37°C 
to 30°C. In addition, this study reported an increase in morphine affinity for its receptor when 
the temperature was raised from 37˚C to 40˚C. This study indicates that during cooling, 
morphine affinity for the µ-receptor is decreased; therefore, it is likely that morphine receptor 
response would be reduced during hypothermia even though the concentrations of morphine 
are likely to be elevated due to reduced morphine clearance.  
Another study evaluated the effect of hypothermia on the drug response to isoflurane in 
children. Liu et al. noted that the isoflurane requirement in children decreased by 5.1% per 
degree Celsius. Furthermore, the isoflurane minimum alveolar concentration values decreased 
from 1.69±0.14% to 1.22±0% at 37°C and 31°C, respectively. The pharmacokinetic properties of 
isoflurane were not evaluated in this study so the overall pharmacokinetic change relative to 
the drug response and dosage is not known so it is unclear if these alterations are due to 
altered pharmacokinetics or pharmacodynamics. Isoflurane is metabolized predominately by 
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CYP2E1 and preclinical studies have demonstrated reduced CYP2E1 activity in the rat model 
during hypothermia. Thus, it is reasonable to postulate that the effects on isoflurane are likely 
due to pharmacokinetics. Future studies should investigate whether a decrease in CYP2E1 
activity is responsible for the decrease in isoflurane response.  
Paralytics. Drug response for the neuromuscular blocking agent vecuronium has been 
studied during therapeutic hypothermia. Mild hypothermia increased the duration of action 
of the second infusion of vecuronium in patients undergoing elective surgery. Another 
study saw a similar increase in the duration of action of vecuronium in healthy volunteers 
during mild hypothermia. An increased duration of action was also seen in atracurium 
during mild hypothermia. In these studies the increase in duration of action was due to 
increase concentrations of the paralytics due to reduced drug clearance (i.e. 
pharmacokinetics). No alteration in the pharmacodynamic response was observed under 
hypothermic conditions. Therefore, unlike morphine response, it appears that the 
pharmacodynamic response to paralytics is not altered during mild hypothermia.  
In summary, therapeutic hypothermia has been shown to affect the drug response of 
analgesics, sedatives, and paralytics. A reduction in drug metabolism and clearance may 
explain part of the response change particularly with paralytics. Conversely, a reduced 
affinity of morphine for the µ-receptor has been reported. Careful pharmacotherapeutic 
monitoring in the clinic during hypothermia treatment may be necessary to prevent a 
potential therapy-drug interaction caused by changes in both drug concentration and in 
drug response during cooling.  
5. Prospectus and future directions 
Therapeutic hypothermia has been shown to be a beneficial neuroprotective therapy in critical 
care. In addition to the benefits for therapeutic hypothermia, there are potential side effects 
that can also occur. The effect of hypothermia on drug metabolism and clearance can lead to 
elevations in drug concentrations. Recent studies have reported that the effect of hypothermia 
on drug metabolism and the degree of change can be specific for the metabolism and 
elimination route. A small number of studies have investigated the effect of hypothermia on 
drug response including analgesics, sedatives and paralytics. The effect on drug response may 
be due to pharmacokinetic and pharmacodynamics alterations during hypothermia.  
However, the effect of therapeutic hypothermia on drug disposition and response is still 
significantly understudied. To date, little is still understood as to how therapeutic 
hypothermia affects the wide array of drugs administered to critically ill patients in the ICU. 
In order to safely use this therapy in patients, it is imperative that we further evaluate the 
potential alterations on drug metabolism and response. Larger clinical trials in humans are 
necessary before we can fully understand the effects of therapeutic hypothermia on drug 
pharmacokinetics. Ultimately by understanding the physiological effects of hypothermia, 
awareness of hypothermia’s effect on drug pharmacokinetics, and learning the potential 
side effects, we will be able to more safely and effectively use this neuroprotective strategy 
in a wide range of critically ill patients.  
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